TG Therapeutics — Third Quarter 2026 Earnings Summary

TG Therapeutics reported third-quarter 2026 total global revenue of approximately $260 million, driven by $233 million in BRIUMVI U.S. net product revenue. The company raised its full-year 2026 total global revenue guidance to approximately $1 billion and increased the BRIUMVI U.S. net product revenue forecast to between $915 million and $920 million. Clinical updates from the MSToronto2026 meeting highlighted positive Phase 3 ENHANCE trial results supporting a simplified single-infusion initiation regimen and encouraging Phase 1 data for a quarterly subcutaneous dosing option. Additionally, the company repurchased approximately $100 million of its common stock during the quarter and maintains a cash position of $556.7 million as of September 30, 2026.